HDL-targeted therapies: progress, failures and future

• High-Density Lipoprotein Modifications: Causes and Functional Consequences in Type 2 Diabetes Mellitus

  2024 Cells article Medicine Cholesterol and Lipid Metabolism Open access

  20

  citations
• High-Density Lipoprotein Modifications: A Pathological Consequence or Cause of Disease Progression?

  2020 Biomedicines article Medicine Cholesterol and Lipid Metabolism Open access

  51

  citations
• RIPK1 Expression Associates With Inflammation in Early Atherosclerosis in Humans and Can Be Therapeutically Silenced to Reduce NF-κB Activation and Atherogenesis in Mice

  2020 Circulation article Immunology and Microbiology Atherosclerosis and Cardiovascular Diseases Open access

  237

  citations
• The effect of food and formulation on the population pharmacokinetics of cholesteryl ester transferase protein inhibitor DRL‐17822 in healthy male volunteers

  2020 British Journal of Clinical Pharmacology article Pharmacology, Toxicology and Pharmaceutics Drug Solubulity and Delivery Systems Open access

  1

  citations
• High Density Lipoprotein pathway as a therapeutic target for coronary heart disease: individual participant meta-analysis in 28,597 individuals with 4197 coronary events

  2020 medRxiv preprint Medicine Lipoproteins and Cardiovascular Health Open access

  4

  citations
• High-Density Lipoproteins and Apolipoprotein A1

  2020 Sub-cellular biochemistry/Subcellular biochemistry book-chapter Medicine Cholesterol and Lipid Metabolism

  109

  citations

6 results